HEIDELBERG, Germany--(BUSINESS WIRE)--mtm laboratories today announced that 10 studies to be presented at the 16th International Congress of Cytology (ICC) confirm the high specificity and sensitivity of the p16INK4a biomarker for cervical dysplasia. p16INK4a is being used by mtm as a biomarker in their proprietary CINtec® products currently marketed for the early detection and diagnosis of cervical cancer.
